Apogenix Strengthens U.S. Patent Position for Lead Immuno-Oncology Candidate APG101

On January 14, 2016 Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, reported that it has received Notices of Allowance from the U.S. Patent and Trademark Office for two key patents for lead immuno-oncology candidate APG101 (Press release, Apogenix, JAN 14, 2016, View Source [SID1234524580]). The so-called method of use patent covers the use of CD95 ligand inhibitors, such as APG101, for the treatment of glioblastoma. This patent is valid at least until 2029. The so-called composition of matter patent protects APG101 as a product as well as its manufacturing process at least until 2033.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Apogenix already has a broad patent portfolio covering APG101. These two patents greatly expand the protection of APG101 and its use in the treatment of glioblastoma," said Thomas Hoeger, Ph.D., CEO of Apogenix. "The prospective granting of these two patents in the most important pharmaceutical market further validates our innovative drug development approach and the therapeutic potential of CD95 ligand inhibitors for the treatment of malignant brain tumors, among other indications."

The efficacy, safety, and tolerability of APG101 were demonstrated in a controlled phase II proof-of-concept trial in patients with recurrent glioblastoma. Treatment with APG101 in combination with radiotherapy has shown clinical superiority in all study endpoints compared to treatment with radiotherapy alone, resulting in an overall survival benefit in glioblastoma patients treated with APG101. Interim data of a phase I trial with APG101 for the treatment of myelodysplastic syndromes further indicate the efficacy of APG101 in this hematological disease.

GP Pharm has recently launched Lutrate® Depot trimestral in Spain

On January 14, 2016 GP Pharm reported that it has recently launched Lutrate Depot trimestral in Spain (Press release, GP Pharm, JAN 14, 2016, View Source [SID1234591043]). Lutrate Depot is a new microsphere formulation of leuprolide acetate. The product is based on the in-home based patented technology of GP Pharm and is indicated for the treatment of prostate cancer. The product complements the offer of GP Pharm in the Spanish market where the 1 month formulation was currently available.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Foundation Medicine, Horizon Healthcare Services, Inc. and COTA Collaborate to Demonstrate the Benefits of a Precision Medicine Treatment Approach for Patients with Metastatic Non-Small Cell Lung Cancer

On January 13, 2016 Foundation Medicine, Inc. (NASDAQ:FMI) reported a three-way collaboration with Horizon Healthcare Services, Inc., New Jersey’s oldest and largest health insurer, and Clinical Outcomes Tracking and Analysis (COTA) to advance precision medicine, improve clinical outcomes and deliver enhanced value to the healthcare system in the treatment of patients with metastatic, non-small cell lung cancer (NSCLC) (Press release, Foundation Medicine, JAN 13, 2016, View Source [SID:1234508781]). The organizations initiated a prospective clinical study measuring changes in survival benefit and total cost savings achieved among patients with previously untreated metastatic NSCLC who undergo comprehensive genomic profiling with FoundationOne. Based on the outcomes, the study enables Horizon to provide its members with coverage for FoundationOne as a critical component of clinical care pathways in the evaluation of patients with metastatic lung cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As thought leaders and innovators in cancer care, the organizations designed the study to support guidelines from the National Comprehensive Cancer Network (NCCN) that specifically recommend broad molecular profiling for patients with NSCLC. These guidelines enable the identification of cancer-driving genomic alterations for which effective targeted therapies may already be approved and available commercially or to enable physicians to appropriately counsel patients regarding the availability of clinical trials. This recommendation by NCCN and the genesis of this trial supports the widespread understanding that cancer is a disease of the genome and that tumors may harbor specific genomic alterations likely to respond to "matched" therapies regardless of its anatomic site of origin.

FoundationOne is a comprehensive genomic profile (CGP) that enables physicians to make treatment decisions for patients with cancer by identifying the molecular growth drivers of their cancers and by helping oncologists match the identified drivers with relevant targeted therapeutic options. Requiring only a small amount of tumor tissue, FoundationOne interrogates the entire coding sequence of 315 cancer-related genes plus select introns from 28 genes that are known to be altered in solid tumors.

"We believe this study design, which embraces the importance of data sharing in molecular information, represents an innovative model of collaboration that will catalyze the consistent integration of comprehensive genomic profiling in clinical care for the treatment of metastatic lung cancer," stated Vincent Miller, M.D., chief medical officer for Foundation Medicine. "We fully expect the study to demonstrate the clinical and health economic benefits of a comprehensive approach versus the use of more limited testing panels and importantly, that these results will support broad reimbursement in this patient population with advanced disease," Miller added.

"Gene-by-gene testing, as is common practice today in metastatic NSCLC, presents clinical and logistical challenges, including missing alterations, insufficient tissue for testing, and a significant loss of precious time in identifying a clinical course of care," said Andrew Pecora, M.D., F.A.C.P., C.P.E., member of Regional Cancer Care Associates and chief innovation officer, Professor and vice president of Cancer Services, John Theurer Cancer Center at HackensackUMC. "The availability of a single CGP assay to accurately identify all known variants from a single sample and to accommodate the expanding list of genomic markers in metastatic NSCLC without necessitating new biopsies is a medical necessity."

"Horizon believes in investigating whether a comprehensive genomic approach could yield the most robust information to guide clinical treatment options – either to approved or investigational therapies – through clinical trials," said Glenn D. Pomerantz, M.D., JD, vice president and chief medical officer with Horizon. "Ultimately, we hope that working with Foundation Medicine on this approach will optimize outcomes for metastatic lung cancer patients."

Patients will be enrolled at Regional Cancer Care Associates (RCCA) and Hackensack Medical University in New Jersey. Patient outcomes will be tracked by Clinical Outcomes Tracking and Analysis (COTA). Horizon Blue Cross of New Jersey will pay for enrolled patients to receive FoundationOne assays as part of the study.

UroGen Pharma Strengthens Leadership Team and Expands Uro-Oncology Clinical Pipeline With Addition of TLR-7 Agonist Phase 2 Asset

On January 13, 2016 UroGen Pharma, Ltd. (formerly known as TheraCoat), a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological pathologies with a focus on uro-oncology, reported the appointment of two key executive officers: Ron Bentsur has joined the company as Chief Executive Officer and Gary Titus has joined the company as Chief Financial Officer (Press release, UroGen Pharma, JAN 13, 2016, View Source [SID1234576502]). In addition, Gil Hakim has been appointed President of Israeli Operations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the fourth quarter of 2015, UroGen completed the acquisition of Vesimune, a TLR-7 agonist immunotherapy drug candidate in a novel, liquid formulation for the treatment of high grade non-muscle invasive bladder cancer, including carcinoma in situ (CIS) bladder cancer, from Telormedix SA. This purchase expands UroGen’s clinical-stage uro-oncology drug candidate pipeline and supports the company’s multi-modality approach for the potential treatment of low and high-grade bladder cancers.

The company is focused on the development of therapeutic candidates to address medical needs across a number of urologic indications, including uro-oncology. UroGen’s uro-oncology drug candidate pipeline is comprised of MitoGel, a novel chemoablation, non-surgical treatment for low-grade Upper Tract Urothelial Carcinoma (UTUC); VesiGelTM, novel chemoablation, non-surgical treatment for low-grade bladder cancer; and Vesimune, a local immunomodulation approach for the treatment of high-grade bladder cancer, including CIS. UroGen has obtained Orphan Drug Designations for MitoGel and Vesimune from the U.S. Food and Drug Administration (FDA). UroGen expects to commence a pivotal trial of MitoGel in low-grade UTUC in the second half of 2016.

Arie Belldegrun, M.D., Chairman of UroGen’s Board of Directors, commented, "On behalf of the Board of Directors, I welcome Ron and Gary to UroGen. Ron brings two decades of biopharmaceutical experience to UroGen and a track record of taking clinical stage drug candidates through the FDA approval process. Gary is a seasoned biotech CFO with expertise in private and public companies, as well as commercial and clinical-stage companies."

Dr. Belldegrun added, "I believe that UroGen is well positioned to advance the clinical development of its exciting pipeline of urology-focused therapeutic candidates, which have the potential to be best-in-class. The prospect of treating a variety of urological cancers locally and without the use of surgery represents a potential shift in the treatment paradigm."

Mr. Bentsur commented, "I am excited to be joining UroGen as CEO at this dynamic time for the company. With no new drugs approved for bladder or upper tract cancers in close to 20 years, this patient population remains dramatically underserved. We have a robust pipeline of clinical-stage drug candidates for uro-oncology and other urologic pathologies, which provides us with an opportunity to offer meaningful improvements over current standards of care."

Mr. Bentsur is an experienced biopharmaceutical CEO and joins UroGen from Keryx Biopharmaceuticals, where he spent six years as Chief Executive Officer. Mr. Bentsur led Keryx through its transition from an early clinical-stage to a fully-integrated commercial biopharmaceutical company following the September 2014 FDA approval and launch of Auryxia for the treatment hyperphosphatemia in dialysis patients. Prior to his tenure at Keryx, Mr. Bentsur served as CEO of XTL Biopharmaceuticals. Mr. Bentsur serves as a Director of Stemline Therapeutics, Inc. and Chairman of Advanced Inhalation Technologies, Ltd.

Mr. Titus is an experienced financial professional with more than 20 years of experience in the healthcare and life sciences arena. Most recently, Mr. Titus served as the Chief Financial Officer of BioCardia, a private, cell-based regenerative medicine company. Prior to that, he served as Chief Financial Officer of SciClone Pharmaceuticals, a commercial-stage biotechnology company. Mr. Titus was previously Chief Financial Officer of Kosan Biosciences until it was acquired by Bristol Myers Squibb. Mr. Titus serves as Chairman of ImmunoCellular Therapeutics Ltd.

About Bladder Cancer and Upper Tract Urothelial Carcinoma (UTUC)

Bladder cancer is the fourth most common cancer in men and ninth in women. In 2015, an estimated 74,000 adults were diagnosed with bladder cancer in the United States. In 2012, there were an estimated 577,403 people living with bladder cancer in the United States. First line treatment of bladder cancer comprises the surgical removal of the tumor, a procedure known as Trans-Urethral Resection of a Bladder Tumor, or TURBT, followed by periodic adjuvant chemotherapy instillations. Bladder cancer is one of the most expensive cancers per patient to treat due to high recurrence rates, intensive surveillance strategies, and expensive treatment costs. The lifetime management of bladder cancer may cost as much as $187,000 per patient, or an aggregate of $3.98 billion annually, in the United States alone. UTUC comprises approximately 10% of renal neoplasms and approximately 5% of urothelial carcinomas. Minimally invasive organ-sparing endoscopic procedures have shown favorable survival data in select patients with small, low grade tumors. However, recurrence rates can reach as high as 90%. Radical nephrectomy (kidney removal) with excision of an ipsilateral bladder cuff remains the standard of care for the treatment of UTUC.

FORMA THERAPEUTICS AND CANCER RESEARCH TECHNOLOGY FORM A THIRD VIRTUAL COMPANY TO ADVANCE DEUBIQUITINATION ASSETS

On January 11, 2016 FORMA Therapeutics and Cancer Research Technology, reported the formation of a third new virtual Asset Discovery and Development Company (ADDCos) with novel chemical matter targeting an undisclosed deubiquitinating enzyme (DUB) (Press release, Forma Therapeutics, JAN 12, 2016, View Source [SID:1234509341]). ADDCos are virtual companies that rapidly advance drug discovery innovations in a compelling scientific area through the collaboration of academic thought leaders, FORMA drug discovery scientists and a world class development network.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This achievement is the result of an ongoing long-term initiative between FORMA and Cancer Research Technology, the commercial arm of Cancer Research UK, to discover innovative tools, technologies and therapeutic drug candidates against a variety of DUBs that regulate protein homeostasis. Under the agreement, FORMA is pairing its ultra-efficient drug discovery and early development capabilities with expertise from Cancer Research Technology’s Discovery Laboratories and the exclusive world-class academic network of Cancer Research UK scientists.

Protein ubiquitination, a highly regulated cellular process controlled in part by DUBs to maintain protein homeostasis with appropriate protein levels and function, contributes to a large number of wide-ranging human diseases when aberrantly dysregulated. DUBs, as members of diverse protein complexes, are key regulators of ubiquitin recycling, processing, proofreading and disassembly. DUBs contain a catalytic domain surrounded by one or more accessory domains, some of which contribute to target recognition, and collectively represent molecular features ideally suited for therapeutic intervention.

"DUBs continue to represent highly attractive discovery targets warranting further exploration," stated Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics. "The evolution of R&D across a distributed network of diverse scientific disciplines allows FORMA to rapidly and creatively advance research discoveries into clinical candidates."

Keith Blundy, CEO of Cancer Research Technology, said: "This partnership has proven to yield exciting biology and translational outcomes, when pairing complementary skills and capabilities together within a unique business structure. We look forward seeing such research discoveries develop into new medicines offering breakthrough treatments to cancer patients worldwide."